The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we have evidence from analyzing phase three trials that if you're low arra that you you have a much enhanced sensitivity to this dual doublet based therapy so one could surmise that if you're somebody with a localized tumor that's of higher grade and you're going to have radiation you'd want to know your arra score for example because that may inform whether or not you should intensify your ADT or or just get standard ADT
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so one could surmise that if you're somebody with a localized tumor that's of higher grade and you're going to have radiation you'd want to know your arra score for example because that may inform whether or not you should intensify your ADT or or just get standard ADT